JOACHIM MAUS,PETER JUERGEN CNOTA,ISTVAN SZELENYI,BEATRIX FYRNYS
申请号：
HRP20120286
公开号：
HRP20120286T1
申请日:
2012.03.30
申请国别(地区):
HR
年份:
2012
代理人:
摘要：
The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R,R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer(R).Uporaba kombinacije topičkog R,R-glikopirolata ili njegove fiziološki prihvatljive soli s inhibitorima (PDE) 4 fosfodiesteraze odabrane iz skupine koja sadrži rolipram, roflumilast ili njihove fiziološki prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bronhijalne astme ili kronične opstruktivne bolesti pluća (COPD). Patent sadrži još 9 patentnih zahtjeva.
